Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frederick L Locke

Showing results (21-30 of 234) with videos related to

Pageof 24
Sort By:
Blood|February 17, 2023
How I treat cytopenias after CAR T-cell therapyTania Jain, Timothy S Olson, Frederick L Locke
Journal of the National Cancer Institute|January 11, 2015
Merkel cell carcinoma and immunosuppression: what we still need to knowFrederick L Locke, Dana E Rollison, Vernon K Sondak
Proceedings. Biological Sciences|March 24, 2021
The roles of T cell competition and stochastic extinction events in chimeric antigen receptor T cell therapyGregory J Kimmel, Frederick L Locke, Philipp M Altrock
Proceedings. Biological Sciences|February 9, 2022
Correction to 'The roles of T-cell competition and stochastic extinction events in CAR T-cell therapy'Gregory J Kimmel, Frederick L Locke, Philipp M Altrock
The New England Journal of Medicine|March 15, 2018
CAR T-Cell Therapy in Large B-Cell LymphomaSattva S Neelapu, Frederick L Locke, William Y Go
JAMA Oncology|November 8, 2019
Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma: A ReviewFrederick L Locke, William Y Go, Sattva S Neelapu
Immunotherapy|April 29, 2015
An update on current and prospective immunotherapies for chronic lymphocytic leukemiaJosephine N Emole, Frederick L Locke, Javier Pinilla-Ibarz
Immunotherapy|September 4, 2013
Immunotherapy strategies for multiple myeloma: the present and the futureFrederick L Locke, Taiga Nishihori, Melissa Alsina, et al.
Oncology and Therapy|November 15, 2021
Patient Perspectives on Health-Related Quality of Life in Diffuse Large B-Cell Lymphoma Treated with Car T-Cell Therapy: A Qualitative StudyRebecca Cheng, Kayla Scippa, Frederick L Locke, et al.
Reviews on Recent Clinical Trials|May 14, 2008
Implications of FLT3 mutations in the therapy of acute myeloid leukemiaRyan J Mattison, Kelly R Ostler, Frederick L Locke, et al.
Pageof 24

Showing results (21-30 of 234) with videos related to

Sort By:
Pageof 24
Blood|February 17, 2023
How I treat cytopenias after CAR T-cell therapyTania Jain, Timothy S Olson, Frederick L Locke
Journal of the National Cancer Institute|January 11, 2015
Merkel cell carcinoma and immunosuppression: what we still need to knowFrederick L Locke, Dana E Rollison, Vernon K Sondak
Proceedings. Biological Sciences|March 24, 2021
The roles of T cell competition and stochastic extinction events in chimeric antigen receptor T cell therapyGregory J Kimmel, Frederick L Locke, Philipp M Altrock
Proceedings. Biological Sciences|February 9, 2022
Correction to 'The roles of T-cell competition and stochastic extinction events in CAR T-cell therapy'Gregory J Kimmel, Frederick L Locke, Philipp M Altrock
The New England Journal of Medicine|March 15, 2018
CAR T-Cell Therapy in Large B-Cell LymphomaSattva S Neelapu, Frederick L Locke, William Y Go
JAMA Oncology|November 8, 2019
Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma: A ReviewFrederick L Locke, William Y Go, Sattva S Neelapu
Immunotherapy|April 29, 2015
An update on current and prospective immunotherapies for chronic lymphocytic leukemiaJosephine N Emole, Frederick L Locke, Javier Pinilla-Ibarz
Immunotherapy|September 4, 2013
Immunotherapy strategies for multiple myeloma: the present and the futureFrederick L Locke, Taiga Nishihori, Melissa Alsina, et al.
Oncology and Therapy|November 15, 2021
Patient Perspectives on Health-Related Quality of Life in Diffuse Large B-Cell Lymphoma Treated with Car T-Cell Therapy: A Qualitative StudyRebecca Cheng, Kayla Scippa, Frederick L Locke, et al.
Reviews on Recent Clinical Trials|May 14, 2008
Implications of FLT3 mutations in the therapy of acute myeloid leukemiaRyan J Mattison, Kelly R Ostler, Frederick L Locke, et al.
Pageof 24